COVID-19: Vaccines and Therapeutics
A new poll by Gallup is showing sharp declines in Americans’ willingness to be vaccinated for the SARS-CoV-2 coronavirus.
Drug maker Johnson & Johnson Oct. 12 announced the pause of its large-scale, pivotal, multi-country phase 3 trial for its JNJ-78436735 COVID-19 vaccine candidate.
The Food and Drug Administration released guidance and a briefing document outlining the key data needed to support an emergency use authorization for a COVID-19 vaccine candidate and further explaining the EUA process.
The National Academies of Science, Engineering and Medicine released A Framework for Equitable Allocation of Vaccine for the Novel Coronavirus to assist and guide the federal government and decision-making bodies, including the Advisory Committee on Immunization Practices, as well as state, tribal…
Joint AHA, AAMC Statement on NASEM Report on Equitable Allocation of a COVID-19 Vaccine.
An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it well, the National Institutes of Health reports.
More than 200,000 of our friends, family members, fellow citizens and front-line workers have succumbed to COVID-19 since March. To put that in context, that’s approximately the same as the population of Salt Lake City, Utah.
The Centers for Disease Control and Prevention awarded $200 million in Coronavirus Aid, Relief, and Economic Security Act funds to help states, territories and other jurisdictions prepare to distribute and administer COVID-19 vaccine.
Johnson & Johnson said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
This Member Advisory summarizes the federal strategy for the public distribution of COVID-19 vaccines.